Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.

Stella F, Pedrazzini E, Baialardo E, Fantl DB, Schutz N, Slavutsky I.

Blood Cells Mol Dis. 2014 Jun 24. pii: S1079-9796(14)00057-6. doi: 10.1016/j.bcmd.2014.05.006. [Epub ahead of print]

PMID:
24973170
[PubMed - as supplied by publisher]
2.

Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression.

Panero J, Stanganelli C, Arbelbide J, Fantl DB, Kohan D, García Rivello H, Rabinovich GA, Slavutsky I.

Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):134-9. doi: 10.1016/j.bcmd.2013.10.002. Epub 2013 Nov 14.

PMID:
24239198
[PubMed - in process]
3.

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

PMID:
23974982
[PubMed - indexed for MEDLINE]
4.

Glutathione S-transferase P1 mRNA expression in plasma cell disorders and its correlation with polymorphic variants and clinical outcome.

Stella F, Weich N, Panero J, Fantl DB, Schutz N, Fundia AF, Slavutsky I.

Cancer Epidemiol. 2013 Oct;37(5):671-4. doi: 10.1016/j.canep.2013.07.004. Epub 2013 Aug 14.

PMID:
23953887
[PubMed - indexed for MEDLINE]
5.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International Myeloma Working Group.

Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. Review.

PMID:
23288300
[PubMed - indexed for MEDLINE]
6.

Acute loss of vision as the initial symptom of multiple myeloma.

Vázquez FJ, Sobenko N, Schutz N, Altszul M, Lagruta I, Mateos MV, Fantl D.

Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):148-50. doi: 10.1016/j.clml.2011.11.005. Epub 2012 Jan 24. Review. No abstract available.

PMID:
22277575
[PubMed - indexed for MEDLINE]
7.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].

PMID:
21799510
[PubMed - indexed for MEDLINE]
8.

New recurrent chromosome alterations in patients with multiple myeloma and plasma cell leukemia.

Stella F, Pedrazzini E, Rodríguez A, Baialardo E, Kusminsky G, Arbelbide J, Fantl DB, Slavutsky I.

Cytogenet Genome Res. 2011;134(4):249-59. doi: 10.1159/000329479. Epub 2011 Jul 5.

PMID:
21734361
[PubMed - indexed for MEDLINE]
9.

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.

Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group.

Leukemia. 2010 Oct;24(10):1700-12. doi: 10.1038/leu.2010.173. Epub 2010 Sep 2. Review.

PMID:
20811404
[PubMed - indexed for MEDLINE]
10.

[Nodular hepatic lesions secondary to multiple myeloma].

Vázquez FJ, Funtowicz G, Rivello HG, Schutz N, Fantl D, Nucifora E.

Medicina (B Aires). 2010;70(4):311-5. Spanish.

PMID:
20679049
[PubMed - indexed for MEDLINE]
11.

Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Panero J, Arbelbide J, Fantl DB, Rivello HG, Kohan D, Slavutsky I.

Mol Med. 2010 Nov-Dec;16(11-12):471-8. doi: 10.2119/molmed.2010.00057. Epub 2010 Jul 14.

PMID:
20644899
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group.

Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Review.

PMID:
20410922
[PubMed - indexed for MEDLINE]
13.

DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance.

Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I.

Ann Hematol. 2010 Feb;89(2):191-9. doi: 10.1007/s00277-009-0818-3.

PMID:
19727727
[PubMed - indexed for MEDLINE]
14.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG.

Leukemia. 2009 Oct;23(10):1904-12. doi: 10.1038/leu.2009.127. Epub 2009 Jun 25.

PMID:
19554029
[PubMed - indexed for MEDLINE]
15.

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S; IMWG.

Leukemia. 2009 Oct;23(10):1716-30. doi: 10.1038/leu.2009.122. Epub 2009 Jun 4. Review.

PMID:
19494840
[PubMed - indexed for MEDLINE]
16.

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG.

Leukemia. 2009 Sep;23(9):1545-56. doi: 10.1038/leu.2009.89. Epub 2009 May 7. Review.

PMID:
19421229
[PubMed - indexed for MEDLINE]
17.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20. Review.

PMID:
19020545
[PubMed - indexed for MEDLINE]
18.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators.

N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.

PMID:
18753647
[PubMed - indexed for MEDLINE]
Free Article
19.

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.

Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group.

Leukemia. 2008 Aug;22(8):1479-84. doi: 10.1038/leu.2008.127. Epub 2008 May 29. No abstract available. Erratum in: Leukemia. 2008 Aug;22(8):1649. Randall, L [corrected to Randall, RL].

PMID:
18509352
[PubMed - indexed for MEDLINE]
20.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation.

Hematol J. 2003;4(6):379-98. Review. Erratum in: Hematol J. 2004;5(3):285.

PMID:
14671610
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk